The value of chest and skeletal staging in parosteal osteosarcoma: two-centre experience and literature review.


Journal

Skeletal radiology
ISSN: 1432-2161
Titre abrégé: Skeletal Radiol
Pays: Germany
ID NLM: 7701953

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 01 06 2020
accepted: 14 07 2020
revised: 14 07 2020
pubmed: 25 7 2020
medline: 25 6 2021
entrez: 25 7 2020
Statut: ppublish

Résumé

To determine the value of chest and skeletal staging in patients with parosteal osteosarcoma (POS), and the incidence of late local and chest recurrence. Retrospective review of patients across two institutions with histological confirmation of POS diagnosed between January 2007 and March 2020. Data collected included age, sex, skeletal location, results of chest CT and whole-body bone scintigraphy (WB-BSc) or whole-body MRI (WB-MRI) obtained at initial diagnosis. The histological tumour grade based on surgical resection specimens was classified as low-grade POS (LG-POS) and dedifferentiated POS (DD-POS). Findings of chest CT and skeletal staging were correlated with tumour grade. Follow-up chest CT and MRI studies were reviewed to determine the rate of late lung metastases and local recurrence. There were 27 males and 44 females, mean age 33 years (range 12-79 years). The femur (n = 43) and tibia (n = 14) were the most commonly involved bones. From surgical resection histology, 42 (59.2%) were LG-POS and 29 (40.8%) were DD-POS. WB-BSc/WB-MRI showed no skeletal metastases, while 1 case of DD-POS presented with bilateral calcified lung metastases. At follow-up, 7 patients (9.9%) developed lung metastases (mean of 18.9 months, range 10-48 months) from initial presentation, of which all were DD-POS. All but 1 patient who developed subsequent lung metastases had a local recurrence. Skeletal staging is unlikely to be of value in POS. Staging chest CT is very unlikely to demonstrate lung metastases in LG-POS and could be limited to DD-POS, particularly at the time of local recurrence.

Identifiants

pubmed: 32705301
doi: 10.1007/s00256-020-03557-y
pii: 10.1007/s00256-020-03557-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

301-309

Références

Klein MJ, Siegal GP. Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol. 2006;125(4):555–81.
doi: 10.1309/UC6KQHLD9LV2KENN
Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J. 2018;4:12.
doi: 10.1051/sicotj/2017028
Hang JF, Chen PC. Parosteal osteosarcoma. Arch Pathol Lab Med. 2014 May;138(5):694–9.
doi: 10.5858/arpa.2013-0030-RS
Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon, France: IARC Press; 2013.
Miller BJ, Cram P, Lynch CF, Buckwalter JA. Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. J Bone Joint Surg Am. 2013;95(13):e89.
doi: 10.2106/JBJS.L.01189
Gerrand C, Athanasou N, Brennan B, et al. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res BioMed Central. 2016;6(1):7.
doi: 10.1186/s13569-016-0047-1
Casali PG, Bielack S, Abecassis N et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct;29 Suppl 4:iv79-iv95.
Bertoni F, Bacchini P, Staals EL, et al. Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer. 2005;103(11):2373–82.
doi: 10.1002/cncr.21039
Jelinek JS, Murphey MD, Kransdorf MJ, et al. Parosteal osteosarcoma: value of MR imaging and CT in the prediction of histologic grade. Radiology. 1996;201:837–42.
doi: 10.1148/radiology.201.3.8939240
Okada F, Frassica FJ, Sim FH, et al. Parosteal osteosarcoma: a clinicopathological study. J Bone Joint Surg Am. 1994;76(3):366–78.
doi: 10.2106/00004623-199403000-00007
Cassone AEm Camargo OP, Croci AT, et al. Paraosteal osteosarcoma. Rev Bras Ortop. 1998; 33 (11).
Unni KK, Dahlin DC, Beabout JW, et al. Parosteal osteogenic sarcoma. Cancer. 1976;37:2466–75.
doi: 10.1002/1097-0142(197605)37:5<2466::AID-CNCR2820370540>3.0.CO;2-G
Hoshi M, Matsumoto S, Manabe J. Oncologic outcome of parosteal osteosarcoma. Int J Clin Oncol. 2006;11(2):120–6.
doi: 10.1007/s10147-005-0545-2
Lin HY, Hondar Wu HT, Wu PK, et al. Can imaging distinguish between low-grade and dedifferentiated parosteal osteosarcoma? J Chin Med Assoc. 2018;81(10):912–9.
doi: 10.1016/j.jcma.2018.01.014
Song WS, Jeon DG, Cho WH, et al. Clinical outcome of paraosteal osteosarcoma. J Korean Bone Joint Tumor Soc. 2013;19(1):20–7.
doi: 10.5292/jkbjts.2013.19.1.20
Lindell MM Jr, Shirkhoda A, Raymond AK, Murray JA, Harle TS. Parosteal osteosarcoma: radiologic-pathologic correlation with emphasis on CT. AJR Am J Roentgenol. 1987;148:323–8.
doi: 10.2214/ajr.148.2.323
Tariq MU, Uddin N, Ahmed A. Challenges and pitfalls in diagnosis of paraosteal osteosarcoma: a clinicopathologic study of 23 cases. Journal of Solid Tumours. 2016;6(2):17–24.
Levine E, De Smet AA, Huntrakoon M. Juxtacortical osteosarcoma: a radiologic and histologic spectrum. Skelet Radiol. 1985;14(1):38–46.
doi: 10.1007/BF00361191
Schajowicz F, McGuire MH, Santini Araujo E, et al. Osteosarcomas arising on the surfaces of long bones. J Bone Joint Surg Am. 1988;70:555–64.
doi: 10.2106/00004623-198870040-00012
Ritschl P, Wurnig C, Lechner G, et al. Parosteal osteosarcoma. 2–23-year follow-up of 33 patients. Acta Orthop Scand. 1991;62(3):195–200.
doi: 10.3109/17453679108993592
Sheth DS, Yasko AW, Raymond AK, et al. Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer. 1996;78(10):2136–45.
doi: 10.1002/(SICI)1097-0142(19961115)78:10<2136::AID-CNCR14>3.0.CO;2-#
Funovics PT, Bucher F, Toma CD, et al. Treatment and outcome of parosteal osteosarcoma: biological versus endoprosthetic reconstruction. J Surg Oncol. 2011;103(8):782–9.
doi: 10.1002/jso.21859
Han I, Oh JH, Na YG, et al. Clinical outcome of parosteal osteosarcoma. J Surg Oncol. 2008;97(2):146–9.
doi: 10.1002/jso.20902
Temple HT, Scully SP, O'Keefe RJ, et al. Clinical outcome of 38 patients with juxtacortical osteosarcoma. Clin Orthop Relat Res. 2000;373:208–17.
doi: 10.1097/00003086-200004000-00025
Takeuchi K, Morii T, Yabe H, et al. Dedifferentiated parosteal osteosarcoma with well-differentiated metastases. Skelet Radiol. 2006;35(10):778–82.
doi: 10.1007/s00256-005-0066-0
Nodomi S, Umeda K, Okamoto T, et al. A pediatric case of metastatic conventional Parosteal osteosarcoma treated with multidrug chemotherapy. Pediatr Blood Cancer. 2016;63(8):1471–3.
doi: 10.1002/pbc.26052
Caparica R, Mak MP, Rocha CH, et al. Pulmonary nodules in patients with non-pulmonary cancer: not always metastases. J Glob Oncol. 2016;2(3):138–44.
doi: 10.1200/JGO.2015.002089
Ghosh KM, Lee LH, Beckingsale TB, et al. Indeterminate nodules in osteosarcoma: what’s the follow-up? Br J Cancer. 2018;118(5):634–8.
doi: 10.1038/bjc.2017.453
Jackson JB 3rd, Kneisl JS. Parosteal osteosarcoma of the 2nd metatarsal. Am J Orthop (Belle Mead NJ). 2013;42(12):557–560.
Tozum H, Aydemir AN, Demiroglu M, Ozkan K, Ceyran AB, Kılıc B. A rare rib lesion due to parosteal osteosarcoma: a case report. J Med Case Rep. 2019;13(1):19.
doi: 10.1186/s13256-018-1958-7
Sanghavi S, Wahegaonkar A, Panchwagh Y, Kharat A. Parosteal osteosarcoma of the distal radius mimicking an osteochondroma-a diagnostic misadventure. J Hand Surg Am. 2017;42(12):1038.e1–1038.e10.
Gupta S, Parikh S, Goel S. Parosteal osteosarcoma of mandible: a rare case report. J Cancer Res Ther. 2018;14(2):471–4.
pubmed: 29516945
Kumar VS, Barwar N, Khan SA. Surface osteosarcomas: diagnosis, treatment and outcome. Indian J Orthop. 2014;48(3):255–61.
doi: 10.4103/0019-5413.132503
Xie L, Huang W, Wang H, et al. Risk factors for lung metastasis at presentation with malignant primary osseous neoplasms: a population-based study. J Orthop Surg Res. 2020;15(1):32.
doi: 10.1186/s13018-020-1571-5
Jeffree GM, Price CH, Sissons HA. The metastatic patterns of osteosarcoma. Br J Cancer. 1975;32(1):87–107.
doi: 10.1038/bjc.1975.136
Salah S, Ahmad R, Sultan I. Osteosarcoma with metastasis at initial diagnosis: current outcomes and prognostic factors in the context of a comprehensive cancer center. Molecular and Clinical Oncology. 2014;2:811–6.
doi: 10.3892/mco.2014.325
Liu F, Zhang Q, Zhou D, et al. Effectiveness of
doi: 10.1186/s12885-019-5488-5
Hurley C, McCarville MB, Shulkin BL, et al. Comparison of (18) F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma. Pediatr Blood Cancer. 2016;63(8):1381–6.
doi: 10.1002/pbc.26014

Auteurs

R Rajakulasingam (R)

Department of Medical Imaging, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, HA7 4LP, UK. Ramanan.rajakulasingam1@nhs.net.

V Attard (V)

Department of Medical Imaging, Mater Dei Hospital, Msida, MSD, 2090, Malta.

R Botchu (R)

Department of Medical Imaging, Royal Orthopaedic Hospital, The Woodlands, Bristol Road South, Birmingham, B31 2AP, UK.

S L James (SL)

Department of Medical Imaging, Royal Orthopaedic Hospital, The Woodlands, Bristol Road South, Birmingham, B31 2AP, UK.

A Saifuddin (A)

Department of Medical Imaging, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, HA7 4LP, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH